Bath & Body Works (NYSE:BBWI) Releases Q4 2024 Earnings Guidance

Bath & Body Works (NYSE:BBWI) issued an update on its fourth quarter 2024 earnings guidance on Monday morning. The company provided EPS guidance of 1.940-2.070 for the period, compared to the consensus EPS estimate of 1.970. The company issued revenue guidance of $2.7 billion-$2.8 billion, compared to the consensus revenue estimate of $2.7 billion. Bath & Body Works also updated its Q4 guidance to $1.94-2.07 EPS.

Bath & Body Works Trading Down 0.1 %

Bath & Body Works stock opened at $30.71 on Monday. Bath & Body Works has a 12 month low of $26.20 and a 12 month high of $52.99. The stock’s 50 day simple moving average is $30.55 and its two-hundred day simple moving average is $35.83. The firm has a market cap of $6.73 billion, a PE ratio of 7.44, a P/E/G ratio of 0.98 and a beta of 1.79.

Bath & Body Works (NYSE:BBWI) last announced its earnings results on Wednesday, August 28th. The company reported $0.37 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.35 by $0.02. Bath & Body Works had a negative return on equity of 41.94% and a net margin of 12.69%. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.54 billion. On average, equities research analysts forecast that Bath & Body Works will post 3.18 EPS for the current year.

Bath & Body Works Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 6th. Investors of record on Friday, November 22nd will be paid a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 2.61%. The ex-dividend date of this dividend is Friday, November 22nd. Bath & Body Works’s dividend payout ratio is currently 19.37%.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Morgan Stanley reduced their price objective on Bath & Body Works from $51.00 to $48.00 and set an “overweight” rating for the company in a research note on Thursday. Deutsche Bank Aktiengesellschaft reduced their price objective on Bath & Body Works from $57.00 to $54.00 and set a “buy” rating for the company in a research note on Monday, August 26th. UBS Group reduced their price objective on Bath & Body Works from $52.00 to $38.00 and set a “neutral” rating for the company in a research note on Thursday, August 29th. Robert W. Baird reduced their price objective on Bath & Body Works from $54.00 to $45.00 and set an “outperform” rating for the company in a research note on Thursday, August 29th. Finally, Evercore ISI reduced their price objective on Bath & Body Works from $45.00 to $35.00 and set an “in-line” rating for the company in a research note on Wednesday, August 28th. One research analyst has rated the stock with a sell rating, six have given a hold rating and nine have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $42.25.

Insider Activity at Bath & Body Works

In other news, CEO Gina Boswell bought 6,000 shares of the stock in a transaction that occurred on Wednesday, October 9th. The stock was bought at an average cost of $29.64 per share, for a total transaction of $177,840.00. Following the acquisition, the chief executive officer now directly owns 242,987 shares of the company’s stock, valued at $7,202,134.68. The trade was a 2.53 % increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. 0.27% of the stock is currently owned by company insiders.

Bath & Body Works Company Profile

Bath & Body Works, Inc operates a specialty retailer of home fragrance, body care, and soaps and sanitizer products. It sells its products under the Bath & Body Works, White Barn, and other brand names through retail stores and e-commerce sites located in the United States and Canada, as well as through international stores operated by partners under franchise, license, and wholesale arrangements.